aiwiki.page
English
Health / Diseases & Symptoms / ventricular-fibrillation

Ventricular Fibrillation

Ventricular fibrillation is a disorganized ventricular heart rhythm that abolishes effective circulation and is a major cause of sudden cardiac arrest.

37 keywords1 linked from11 not yet writtenWritten by AI
Atrial fibrillat…Cardiopulmonary…Electrophysiolog…Adenosine Tripho…Coronary artery…FibrosisChannelopathyEpilepsyVentricula…

Ventricular fibrillation is a life-threatening disturbance of the heart’s electrical activity in which the ventricular muscle is activated rapidly and irregularly rather than contracting in a coordinated sequence. The ventricles consequently fail to generate effective blood flow, producing cardiac arrest. Consciousness is usually lost within seconds, and sustained interruption of circulation causes progressive injury to the brain and other organs. Ventricular fibrillation is distinct from atrial fibrillation, which affects the upper chambers and ordinarily does not immediately abolish the circulation.

Its importance lies in the combination of abrupt onset, rapid physiological deterioration, and potential reversibility. Electrical defibrillation can terminate the abnormal rhythm, while cardiopulmonary resuscitation provides limited circulation during the arrest. Outcomes depend strongly on the circumstances of collapse, the underlying disease, and the interval before effective treatment. Ventricular fibrillation may complicate coronary disease, structural heart disease, inherited electrical disorders, metabolic disturbances, or specific external triggers. Understanding it therefore connects cellular electrophysiology with emergency care, inherited disease assessment, long-term prevention, and the organization of community resuscitation systems.

Electrical mechanisms and loss of circulation

A normal heartbeat begins with organized electrical activation that travels through the atria, the atrioventricular node, and the specialized ventricular conduction system. Activation of ventricular muscle follows a coordinated sequence, allowing the two ventricles to develop pressure and eject blood. During ventricular fibrillation, electrical activation is fragmented across the ventricular myocardium. Different regions depolarize and recover at different times, so local muscle activity does not produce a coordinated pumping action. The heart is electrically active but mechanically ineffective; this distinguishes fibrillation from asystole, in which detectable ventricular electrical activity is absent.

The relevant electrophysiology involves interactions between the movement of an electrical wavefront and the recovery of the tissue behind it. A wave can circulate repeatedly if it encounters a pathway through which previously activated muscle has become excitable again. This process, called re-entry, is favored by slow conduction, unequal recovery times, and anatomical or functional obstacles. In simplified descriptions, the excitation wavelength is expressed as

λ=v×Tref,\lambda = v \times T_{\mathrm{ref}},

where vv is conduction velocity and TrefT_{\mathrm{ref}} is the refractory period. A circuit can sustain re-entry when its available pathway accommodates the circulating wave. Real ventricular tissue is three-dimensional and heterogeneous, so this relationship is explanatory rather than a complete predictive model.

Ventricular fibrillation can involve multiple interacting wavelets, rapidly rotating activation patterns, and waves that repeatedly split or extinguish. These mechanisms are not mutually exclusive. Myocardial scars create fixed barriers and narrow conducting channels, whereas acute ischemia produces changing electrical gradients. Differences in activation across the thickness of the ventricular wall add further complexity. A premature beat can initiate fibrillation when it reaches some regions that have recovered excitability while adjacent regions remain refractory. The Purkinje conduction system can also provide initiating impulses, particularly in some forms of recurrent fibrillation.

Once effective circulation stops, coronary blood flow falls sharply. Oxygen deprivation reduces adenosine triphosphate availability, alters ion gradients, and impairs membrane pumps. Acidosis and extracellular potassium accumulation further disturb conduction and recovery. These changes help explain why the rhythm and its responsiveness to shocks evolve during an untreated arrest. On a surface recording, initially large-amplitude fibrillatory activity may become lower in amplitude, although amplitude is influenced by electrode position, body characteristics, and equipment settings as well as myocardial condition.

Defibrillation interrupts fibrillation by delivering an electric field that changes the electrical state of a sufficient amount of myocardium, preventing ongoing wavefronts from continuing to propagate. It does not simply “restart” an electrically silent heart. Successful termination may be followed by an organized rhythm, another arrhythmia, or a period without effective contraction. Electrical success and restoration of circulation are therefore related but separate outcomes.

Underlying diseases and precipitating events

In adults, coronary artery disease is a major substrate for ventricular fibrillation. Acute coronary obstruction can produce myocardial ischemia, changing membrane potentials, conduction velocity, and recovery in affected tissue. Fibrillation may occur early during an acute myocardial infarction, sometimes before the person reaches medical care. It can also arise in a heart with an old infarct, where surviving muscle bundles within or around a scar provide pathways for abnormal electrical propagation. Ischemia-related fibrillation and scar-related arrhythmias consequently differ in their immediate triggers and longer-term implications.

Structural disorders provide another important group of substrates. Dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, and inflammatory myocardial disease can alter ventricular architecture and electrical properties. Fibrosis interrupts the normal continuity of muscle fibers and creates regions with different conduction characteristics. Ventricular dysfunction and heart failure frequently coexist with these changes, although severe pump impairment is not required for fibrillation to occur. Myocarditis and cardiac sarcoidosis can create arrhythmic risk through combinations of inflammation, tissue injury, and scar formation.

Some affected people have inherited disorders of electrical function without obvious structural abnormalities on routine imaging. These include long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia. Many belong to the broader category of channelopathy, although their molecular mechanisms extend beyond a simple defect in one ion channel. Long QT syndrome can produce torsades de pointes, a form of polymorphic ventricular tachycardia that may deteriorate into fibrillation. Brugada syndrome is associated with a characteristic electrocardiographic pattern and an increased risk of ventricular arrhythmia in susceptible individuals. In catecholaminergic polymorphic ventricular tachycardia, exercise or emotional stress can provoke arrhythmia through abnormal intracellular calcium handling.

Acquired physiological disturbances can initiate or facilitate fibrillation. Marked potassium or magnesium abnormalities, severe oxygen deprivation, electrical injury, and certain drug toxicities are established examples. Drugs that substantially prolong ventricular repolarization can promote torsades de pointes, especially when other susceptibility factors are present. Profound hypothermia can destabilize the myocardium, while fever can reveal or aggravate the electrical phenotype of Brugada syndrome. The relative importance of each factor depends on the individual substrate rather than on the trigger alone.

A distinctive mechanical trigger is commotio cordis, in which a blunt impact to the chest induces ventricular fibrillation without requiring major structural injury to the heart. Experimental and clinical observations associate this event with an impact during a narrow vulnerable phase of repolarization. Another category, idiopathic ventricular fibrillation, is used when an appropriate evaluation does not identify a structural, metabolic, toxic, or recognized inherited cause. This designation can change as follow-up or additional testing reveals a previously unrecognized disorder.

Clinical presentation and rhythm identification

Ventricular fibrillation usually presents as sudden collapse, unresponsiveness, absence of effective circulation, and absent or abnormal breathing. Agonal gasps can occur during cardiac arrest and do not indicate normal ventilation. Brief seizure-like movements may accompany the abrupt loss of cerebral blood flow, sometimes creating confusion with epilepsy. Some people report chest pain, palpitations, breathlessness, or faintness before collapse, but others have no recognized warning symptoms. Because sustained fibrillation does not support adequate circulation, it cannot ordinarily produce a prolonged state of preserved consciousness.

The rhythm is identified using electrocardiography or a defibrillator’s rhythm recording. Typical ventricular fibrillation consists of irregular oscillations with changing amplitude and contour, without consistently identifiable P waves, QRS complexes, or T waves. Descriptions such as “coarse” and “fine” refer chiefly to the amplitude of the recorded waveform. They do not define different underlying diseases, and there is no universally applicable amplitude threshold that determines prognosis or treatment response. Recording gain, filtering, electrode placement, and electrical interference affect the appearance.

The differential diagnosis includes polymorphic ventricular tachycardia, recording artifact, and asystole. Polymorphic ventricular tachycardia retains recognizable ventricular complexes whose shape and electrical axis vary, whereas fibrillation lacks a stable organization of ventricular depolarization. In practice, very rapid polymorphic tachycardia and fibrillation may merge or be difficult to separate on a brief tracing. Both belong to the shockable cardiac arrest rhythms when effective circulation is absent. Pulseless electrical activity is different: the recording shows organized electrical activity, but the heart does not produce a detectable effective pulse.

Artifact can closely resemble fibrillation. Movement, chest compressions, poor electrode contact, and electrical interference may produce a chaotic-looking tracing even when an organized rhythm continues underneath. Clinical rhythm assessment therefore incorporates the patient’s condition and the circumstances of the recording, rather than interpreting the waveform in isolation. Conversely, very low-amplitude fibrillation can resemble asystole. These distinctions matter because defibrillation is directed at fibrillation and pulseless ventricular tachycardia, not at every cause of cardiac arrest.

After circulation has returned, determining why fibrillation occurred becomes a separate diagnostic task. Evaluation commonly integrates the circumstances of the collapse, medication exposure, personal and family medical history, serial electrocardiograms, electrolyte measurements, and assessment for myocardial ischemia. Echocardiography assesses ventricular function and structural abnormalities. Coronary imaging and cardiac magnetic resonance imaging can identify coronary disease, infarct scar, inflammation, or cardiomyopathy. A raised cardiac troponin concentration alone does not establish acute coronary occlusion, because myocardial injury can also accompany the arrest and resuscitation process. In selected unexplained cases, specialist evaluation includes provocative testing and genetic assessment; the significance of a genetic finding depends on its classification and its fit with the clinical phenotype.

Epidemiology and determinants of outcome

Ventricular fibrillation is a major mechanism of sudden cardiac arrest, but the two terms are not interchangeable. Cardiac arrest also occurs with pulseless ventricular tachycardia, pulseless electrical activity, and asystole. Sudden cardiac death describes a fatal outcome under specified temporal and clinical definitions; it does not establish the rhythm responsible. Many deaths occur without rhythm documentation, so neither death certificates nor retrospective accounts can reliably identify all episodes of fibrillation.

The “initial rhythm” in a cardiac arrest registry usually means the first rhythm recorded by a monitor or defibrillator, not necessarily the rhythm present at the moment of collapse. This distinction is fundamental to epidemiology. Untreated ventricular fibrillation may deteriorate into asystole before emergency personnel arrive. A low recorded proportion of fibrillation can therefore reflect longer delays to monitoring as well as differences in underlying disease. Witnessed arrests, particularly those occurring in public settings, are more likely to be documented with a shockable rhythm than unwitnessed arrests discovered much later.

Adult out-of-hospital registries in many high-income settings report shockable initial rhythms in roughly one-fifth to one-third of treated arrests, although proportions differ substantially by population and case definition. Some registries combine fibrillation with pulseless ventricular tachycardia, making a separate fibrillation estimate difficult. In-hospital populations have a different case mix, with more arrests associated with respiratory failure, shock, and advanced systemic illness. Children likewise have a larger proportion of arrests arising from respiratory or circulatory deterioration rather than a primary ventricular arrhythmia.

Several characteristics consistently influence survival: whether the event was witnessed, whether bystander resuscitation occurred, the delay to defibrillation, arrest location, underlying cause, and the quality of subsequent care. An initially shockable rhythm is generally associated with better survival than an initially nonshockable rhythm. However, this association partly reflects differences in cause, duration before recognition, and reversibility. It does not mean that all episodes of fibrillation have a favorable prognosis or that outcomes can be predicted from rhythm alone.

Survival figures must specify their endpoint. Restoration of spontaneous circulation, survival to hospital admission, survival to discharge, and survival with favorable neurological function are distinct measures. Selected groups with witnessed collapse and very early defibrillation can have much better outcomes than an entire regional arrest population. Comparisons between emergency systems also depend on whether untreated cases are counted and how presumed cardiac causes are classified. Utstein reporting conventions were developed to make these definitions more consistent.

Access to recognition and treatment is distributed unevenly. Arrests at home may occur without a trained witness or a nearby defibrillator, whereas some transport hubs, workplaces, and sporting venues have organized response systems. Geography, ambulance response times, socioeconomic conditions, and bystander participation all influence observed outcomes. Ventricular fibrillation is consequently both a clinical event and a subject of public health research into emergency response and unequal access to time-critical care.

Resuscitation and defibrillation

The immediate treatment framework for ventricular fibrillation combines defibrillation with cardiopulmonary resuscitation and correction of reversible contributors. Defibrillation is the intervention that can directly terminate the fibrillatory rhythm. Chest compressions provide a limited substitute for cardiac pumping, generating blood flow to the coronary and cerebral circulations while definitive rhythm treatment is delivered. Compressions do not generally eliminate fibrillation themselves, but they can preserve myocardial viability and improve the conditions for a successful shock.

Modern external defibrillators commonly use biphasic waveforms, in which current reverses direction during the shock. The biological effect depends on the waveform, current flow through the chest, tissue impedance, electrode contact, and the distribution of the electric field. Shock energy is not a direct measurement of how much current reaches each part of the myocardium. Equipment-specific protocols account for these differences. Defibrillation during fibrillation is unsynchronized because no reliable QRS complex exists against which a synchronized shock could be timed.

An automated external defibrillator analyzes the recorded rhythm and determines whether it meets criteria for a shockable rhythm. These devices were developed to make defibrillation possible outside specialist medical settings. Their algorithms distinguish shockable patterns from organized rhythms and asystole, although motion and compression artifact complicate analysis. Manual defibrillators give trained clinicians greater control over rhythm interpretation and energy selection. In either case, interruptions in chest compressions affect circulation, and resuscitation systems are organized around limiting avoidable pauses.

Drug treatment is an adjunct rather than a substitute for electrical therapy. Epinephrine is used during cardiac arrest to increase vascular tone and support coronary perfusion pressure. Amiodarone or lidocaine may be used for fibrillation or pulseless ventricular tachycardia that persists despite shocks. Trial evidence distinguishes improvements in intermediate outcomes, such as hospital admission, from improvements in survival with good neurological function. Magnesium has a specific role in torsades de pointes but is not a routine treatment for every episode of fibrillation. The timing and selection of drugs vary somewhat between professional resuscitation guidelines.

Persistent fibrillation after repeated shocks is often termed refractory ventricular fibrillation, although research definitions differ. Apparent persistence may represent either failure to terminate the rhythm or rapid recurrence after brief termination. Clinicians assess electrode placement, shock delivery, ongoing ischemia, electrolyte abnormalities, and other reversible causes. Alternative pad configurations and double sequential external defibrillation have been studied, but their place in practice is more restricted than that of conventional defibrillation.

Selected centers also use extracorporeal cardiopulmonary resuscitation, in which a mechanical circuit temporarily supplies circulation and oxygenation during otherwise refractory arrest. This approach requires rapid deployment, specialized facilities, and careful patient selection. It does not itself correct the initiating disease or eliminate fibrillation. Resuscitation studies therefore evaluate a coordinated treatment pathway rather than a single device in isolation.

Post-arrest injury and intensive care

Termination of ventricular fibrillation does not end the physiological consequences of the arrest. After restoration of spontaneous circulation, patients may develop post-cardiac arrest syndrome, comprising brain injury, transient myocardial dysfunction, a systemic ischemia–reperfusion response, and the continuing effects of the original disease. These components interact. For example, depressed cardiac function can impair cerebral perfusion, while widespread inflammatory and vascular changes can worsen circulatory instability even after an organized heart rhythm has returned.

The brain is particularly vulnerable because it has high metabolic requirements and limited energy reserves. During arrest, oxygen and glucose delivery fall abruptly. Reperfusion restores essential substrates but can also be accompanied by oxidative stress, disrupted calcium regulation, and injury to small blood vessels. The neurological consequences range from rapid recovery to prolonged disorders of consciousness. Duration without effective circulation is important, but it is not the only determinant: preceding oxygen deprivation, body temperature, resuscitation quality, and subsequent physiological disturbances also matter.

Intensive care includes assessment of oxygenation, ventilation, blood pressure, cardiac function, temperature, and recurrent arrhythmias. Mechanical ventilation is frequently required in unconscious patients. Both insufficient oxygen delivery and excessive ventilation can be harmful through their effects on arterial oxygen and carbon dioxide concentrations and cerebral blood flow. Seizures may occur after arrest and are evaluated clinically and with electroencephalography. Sedatives, metabolic disturbances, and temperature control can complicate interpretation of neurological examinations.

Temperature management has evolved as randomized trials have clarified the effects of different strategies. Earlier trials helped establish the use of induced hypothermia after selected out-of-hospital arrests. Later studies comparing lower temperature targets with controlled normothermia and fever treatment did not establish a universal advantage for deeper cooling in the populations studied. Contemporary care emphasizes deliberate temperature control and prevention of fever in patients who remain unconscious, while particular targets and durations depend on the clinical protocol and patient circumstances.

Treatment of the initiating cause continues alongside organ support. Acute coronary occlusion, when present, can require urgent reperfusion. The role and timing of coronary angiography differ between patients with clear ST-segment elevation and stable patients without it. Randomized studies in selected patients without ST-segment elevation have not shown a general survival advantage from routine immediate angiography over delayed or selective approaches. Hemodynamic instability, ongoing ischemia, and recurrent ventricular arrhythmia remain important clinical distinctions.

Neurological prognosis is assessed through a delayed, multimodal process rather than a single early observation. Examination findings, electrophysiological tests, imaging, and selected biomarkers are interpreted together after relevant confounders have been considered. Recovery can continue beyond discharge. Survivors may experience impaired memory, attention, fatigue, reduced exercise tolerance, anxiety, or post-traumatic stress symptoms. Follow-up and cardiac rehabilitation therefore address both cardiac disease and the wider functional consequences of the arrest.

Recurrence prevention and inherited risk assessment

Long-term management distinguishes an arrhythmia caused by a transient, correctable disturbance from one arising from a persistent substrate. This distinction is not always straightforward. An acute electrolyte abnormality may coexist with myocardial scar, or an apparently isolated episode may reveal an inherited disorder only later. The evaluation therefore considers the timing of the event, ventricular function, coronary anatomy, imaging findings, medication exposure, and family history. “Reversible cause” is a clinical classification, not proof that future risk has disappeared.

An implantable cardioverter-defibrillator, or ICD, can detect and treat recurrent life-threatening ventricular arrhythmias. Secondary-prevention trials established a survival benefit in selected survivors of serious ventricular arrhythmia compared with antiarrhythmic drug strategies. An ICD is commonly considered after ventricular fibrillation when there is an ongoing risk and the event is not attributed solely to a completely reversible cause. Candidacy also depends on the wider clinical condition and expected meaningful survival. Device implantation does not remove the underlying myocardial disease or prevent every arrhythmia from occurring.

ICDs monitor electrical activity and can deliver a shock when their programmed criteria identify a dangerous rhythm. Transvenous systems can also provide pacing, including antitachycardia pacing for suitable ventricular tachycardias. Subcutaneous systems avoid leads within the heart and vasculature but have different pacing capabilities. Device-related complications include infection, lead malfunction, and inappropriate treatment of nonventricular rhythms or electrical noise. Programming is consequently designed to balance prompt treatment of dangerous arrhythmias against unnecessary therapy.

Treatment of the substrate remains important after implantation. Coronary disease, ventricular dysfunction, and inflammatory or inherited disorders require disease-specific management. Beta-blockers and other medications may reduce arrhythmia burden in appropriate conditions. Antiarrhythmic drugs can reduce recurrent episodes and device shocks, although their effects and adverse reactions depend on the disease and drug. Catheter ablation is used in selected patients with recurrent ventricular arrhythmias. In some forms of recurrent fibrillation, a reproducible premature ventricular beat acts as a trigger and can be targeted, often within or near the Purkinje system.

Repeated ventricular arrhythmias over a short interval are described as an electrical storm. This is a clinical syndrome rather than a distinct mechanism: episodes may be driven by acute ischemia, heart failure deterioration, drug effects, electrolyte disturbance, or an established arrhythmic substrate. Management commonly combines treatment of the cause with suppression of sympathetic activation, antiarrhythmic therapy, device assessment, and, in selected cases, ablation. Recurrent shocks can themselves impose substantial physical and psychological burdens.

When an inherited disorder is suspected, evaluation may extend to relatives. Genetic counseling helps place test results in the context of inheritance, variable expression, and the limitations of current testing. A pathogenic variant in a well-established disease gene can support targeted family assessment, but a variant of uncertain significance does not by itself establish the cause of an arrest. Clinical examination, electrocardiography, imaging, and follow-up remain important even when genetic testing is unrevealing.

Historical development and research methods

The recognition of ventricular fibrillation emerged from nineteenth-century experiments on the relationship between electricity and cardiac contraction. In 1850, Moritz Hoffa and Carl Ludwig described fibrillatory ventricular activity during experimental stimulation. John Alexander MacWilliam’s work in the 1880s connected disorganized ventricular activity with sudden failure of the circulation. These observations helped separate fibrillation from theories that attributed sudden cardiac death simply to cessation of all cardiac activity. The key conceptual change was recognition that an electrically active heart could nevertheless be unable to pump blood.

In 1899, Jean-Louis Prévost and Frédéric Battelli demonstrated experimentally that electric shocks could both induce and terminate ventricular fibrillation. Translation to reliable clinical treatment took decades. In 1947, Claude Beck and colleagues reported successful defibrillation during surgery using electrodes applied directly to the exposed heart. Paul Zoll and colleagues reported successful closed-chest defibrillation in humans in 1956. Bernard Lown and collaborators subsequently developed direct-current approaches that helped establish more practical clinical cardioversion and defibrillation in the early 1960s.

Resuscitation became a coordinated clinical practice as electrical therapy was combined with ventilation and external chest compressions. The 1960 report by William Kouwenhoven, James Jude, and Guy Knickerbocker on closed-chest cardiac massage was an important milestone. Mobile coronary care units and portable defibrillators then brought treatment closer to the site of collapse. Later development of automated external defibrillators expanded the range of settings in which a potentially lethal ventricular rhythm could be recognized and treated before arrival at a hospital.

The first human implantation of an automatic implantable defibrillator in 1980, following work led by Michel Mirowski and collaborators, shifted part of prevention from emergency response to continuous internal monitoring and treatment. Subsequent trials clarified which patient groups benefited from implantable devices. Advances in battery technology, rhythm discrimination, leads, and programming reduced device size and altered the balance between efficacy and complications. These developments also created new research questions concerning inappropriate shocks, long-term lead performance, and patient-reported outcomes.

Modern mechanistic research combines surface electrocardiography, intracardiac recordings, optical mapping in experimental preparations, imaging, and computational models. Optical mapping can reveal activation and recovery patterns across tissue with high spatial resolution, while computer models test how ion-channel behavior, tissue geometry, and fibrosis influence wave propagation. Each method has limitations: experimental preparations differ from a living human heart, surface recordings compress three-dimensional activity into a small number of signals, and simulations depend on their assumptions and parameter estimates.

Clinical studies use different designs for different questions. A randomized controlled trial can compare resuscitation interventions, while registries and cohort studies describe real-world treatment and longer-term outcomes. Arrest research is especially sensitive to timing, selection, and endpoint definitions. Trials may distinguish shock termination from sustained return of circulation, or overall survival from survival with favorable neurological function. Studies of waveform analysis and machine learning examine whether physiological information in the fibrillation signal can improve rhythm recognition or treatment timing, but algorithm performance must be evaluated separately from evidence that its use improves patient outcomes.